You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

Mass. Movers

FDA report lifts Aegerion drug

istockphoto.com

Continue reading below

Aegerion Pharmaceuticals Inc. shares jumped Monday after Food and Drug Administration medical reviewers said the Cambridge firm’s proposed drug to treat a rare genetic disorder that causes high cholesterol is effective at reducing it, but there is a potential to cause liver damage. The drug, lomitapide, will be reviewed on Wednesday by a panel of non-FDA medical specialists, which will make recommendations to the agency about whether lomitapide should be approved.

Loading comments...

Wake up with today's top stories.

Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
or
Please enter a valid email
BostonGlobe.com will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com